fingolimod hydrochloride has been researched along with Purpura, Thrombocytopenic, Idiopathic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mukharesh, L; Rothstein, TL | 1 |
| Brown, S; Chan, N; Grigoriadis, G; Yuen, HLA | 1 |
2 other study(ies) available for fingolimod hydrochloride and Purpura, Thrombocytopenic, Idiopathic
| Article | Year |
|---|---|
Fingolimod-induced immune thrombocytopenic purpura (ITP).
Topics: Adult; Fingolimod Hydrochloride; Glucocorticoids; Humans; Immunoglobulins, Intravenous; Methylprednisolone; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Purpura, Thrombocytopenic, Idiopathic; Sphingosine 1 Phosphate Receptor Modulators; Treatment Outcome | 2020 |
Immune thrombocytopenic purpura associated with fingolimod.
Topics: Blood Platelets; Disease Management; Female; Fingolimod Hydrochloride; Glucocorticoids; Humans; Immunologic Factors; Immunosuppressive Agents; Middle Aged; Multiple Sclerosis; Natalizumab; Prednisolone; Purpura, Thrombocytopenic, Idiopathic; Receptors, Fc; Receptors, Lysosphingolipid; Recombinant Fusion Proteins; Thrombopoietin; Treatment Outcome; Young Adult | 2017 |